- Home
- SEE vs ADMA Comparison
SEE vs ADMA Comparison
Compare SEE & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEE
- ADMA
- Stock Information
- Founded
- SEE 1960
- ADMA 2004
- Country
- SEE United States
- ADMA United States
- Employees
- SEE N/A
- ADMA N/A
- Industry
- SEE Major Chemicals
- ADMA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SEE Industrials
- ADMA Health Care
- Exchange
- SEE Nasdaq
- ADMA Nasdaq
- Market Cap
- SEE 3.8B
- ADMA 4.1B
- IPO Year
- SEE N/A
- ADMA N/A
- Fundamental
- Price
- SEE $26.40
- ADMA $21.31
- Analyst Decision
- SEE Buy
- ADMA Strong Buy
- Analyst Count
- SEE 12
- ADMA 4
- Target Price
- SEE $39.33
- ADMA $22.50
- AVG Volume (30 Days)
- SEE 2.4M
- ADMA 3.7M
- Earning Date
- SEE 05-06-2025
- ADMA 05-08-2025
- Dividend Yield
- SEE 3.03%
- ADMA N/A
- EPS Growth
- SEE N/A
- ADMA N/A
- EPS
- SEE 1.81
- ADMA 0.81
- Revenue
- SEE $5,392,600,000.00
- ADMA $426,454,000.00
- Revenue This Year
- SEE N/A
- ADMA $18.45
- Revenue Next Year
- SEE $2.09
- ADMA $26.96
- P/E Ratio
- SEE $14.35
- ADMA $26.31
- Revenue Growth
- SEE N/A
- ADMA 65.16
- 52 Week Low
- SEE $22.78
- ADMA $6.01
- 52 Week High
- SEE $41.14
- ADMA $23.64
- Technical
- Relative Strength Index (RSI)
- SEE 42.24
- ADMA 60.16
- Support Level
- SEE $25.56
- ADMA $17.30
- Resistance Level
- SEE $27.11
- ADMA $22.25
- Average True Range (ATR)
- SEE 1.44
- ADMA 1.50
- MACD
- SEE 0.12
- ADMA 0.16
- Stochastic Oscillator
- SEE 56.83
- ADMA 83.62
About SEE Sealed Air Corporation
Sealed Air is organized via two reporting segments. Food care includes food packaging products like Cryovac, Darfresh, and OptiDure aimed primarily at meats. Product care includes Sealed Air's Bubble Wrap, Instapak, Jiffy mailers, and shrink film packaging systems that cater to industrial and e-commerce applications.
About ADMA ADMA Biologics Inc
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.